WORLDWIDE PATIENT EXPERIENCE WITH ESBRIET

*Countries include Albania, Argentina, Australia, Austria, Belgium, Bulgaria, Brazil, Canada, Chile, Colombia, Croatia, Cyprus, Czech Republic, Denmark, Ecuador, Estonia, Finland, France, Georgia, Germany, Greece, Hong Kong (special administrative region), Hungary, Iceland, Ireland, Israel, Italy, Kosovo, Kuwait, Lithuania, Luxembourg, Macao (special administrative region), Malaysia, Malta, Montenegro, Myanmar, the Netherlands, New Zealand, Norway, Oman, Qatar, Paraguay, Poland, Portugal, Peru, Romania, Russia, Saudi Arabia, Serbia, Singapore, Spain, Slovakia, Slovenia, Sweden, Switzerland, Turkey, Ukraine, the United Arab Emirates, the United Kingdom, the United States, Uruguay. 1
Derived from the volume of global sales of Esbriet and the estimated total amount taken by patients with IPF worldwide, from February 2011 through February 2019. 1
The safety of pirfenidone has been evaluated in more than 1400 subjects, with over 170 subjects exposed to pirfenidone for more than 5 years in clinical trials. Please see the Esbriet safety and tolerability profile. 2